COMPETACT is a new second-line, fixed-dose combination treatment for people with Type 2 diabetes failing on metformin therapy. COMPETACT combines two established oral anti-hyperglycaemic agents with confirmed efficacy (sustained glycaemic effects) and tolerability.
From: www.jcn.co.uk
Spotlight
Posted by Ruslan Abuzant at 12:06 PM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment